ADC Therapeutics (ADCT) Q2 2024 earnings summary

Executive summary

• ZYNLONTA achieved commercial profitability in the first half of 2024, with $34.9M YTD revenue and $17M in Q2, despite a competitive market and sequential sales decline due to ordering variability.

• Operating expenses decreased over 20% year-over-year, reflecting cost-saving initiatives and portfolio prioritization.

• Cash and equivalents stood at $300.1M as of June 30, 2024, bolstered by a $105M equity offering in May.

• Strategic focus remains on hematology, expanding ZYNLONTA into earlier DLBCL lines and indolent lymphomas, and advancing a solid tumor pipeline led by ADCT-601.

• Key clinical progress includes LOTIS-5 nearing full enrollment and LOTIS-7 dose expansion, with data expected by year-end 2024.

Financial highlights

• Q2 2024 product revenue was $17M, down from $19.2M in Q2 2023, mainly due to lower sales volume and higher gross-to-net deductions.

• GAAP net loss for Q2 2024 was $36.5M ($0.38/share); adjusted net loss was $24.4M ($0.25/share), both improved year-over-year.

• Operating expenses for Q2 2024 were $46.5M, down 21% year-over-year; adjusted operating expenses were $44.5M, down 23%.

• R&D expenses fell 22.5% year-over-year to $24.3M in Q2 2024.

• Cash used in operations for the first half of 2024 was $76.9M.

Outlook and guidance

• Commercial business is now self-funding and expected to remain so, with cash runway projected into mid-2026.

• Full LOTIS-5 enrollment and LOTIS-7 Part 2 completion expected by end of 2024, with mature data in H1 2025.

• Initial readouts from ADCT-601 and other pipeline assets anticipated in H2 2024.

• Revenue may fluctuate due to patient demand, therapy duration, and gross-to-net adjustments.